QUEBEC CITY, March 19 /CNW Telbec/ - New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology (179:15871592, 2008) supports the use of a PCA3-based test as a tool for diagnosing prostate cancer. The new study confirms that PCA3, DiagnoCure’s highly specific prostate cancer marker, and the world’s first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
